$PALI
PALISADE BIO, INC. Stock $pali

$pali Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000117184321006102 Filed on August 23, 2021

Income Statement

Concept	2021 Q2	2020 Q2	2020 Q1
Revenue	$0.00	$2.500K	$6.020K
YoY Change	-100.0%	-68.33%	140.8%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.427M	$1.500M	$1.300M
YoY Change	61.8%	54.64%	38.3%
% of Gross Profit
Research & Development	$314.0K	$446.0K	$696.9K
YoY Change	-29.6%	-53.27%	-53.98%
% of Gross Profit
Depreciation & Amortization	-$8.000K	$30.00K	$30.00K
YoY Change	-126.67%	-25.0%	-25.0%
% of Gross Profit
Operating Expenses	$32.86M	$1.841M	$1.996M
YoY Change	1684.79%	-4.43%	-18.81%
Operating Profit	-$32.86M	-$1.841M	-$1.990M
YoY Change	1684.79%	-4.03%	-18.97%
Interest Expense	$655.0K	$11.00K	$2.579K
YoY Change	5854.55%	2069.63%	27.86%
% of Operating Profit
Other Income/Expense, Net	$1.112M	-$10.00K	-$5.585M
YoY Change	-11220.0%	-102.08%	749.49%
Pretax Income	-$31.75M	-$1.950M	-$7.580M
YoY Change	1528.0%	35.42%	143.73%
Income Tax
% Of Pretax Income
Net Earnings	-$31.75M	-$1.851M	-$2.384M
YoY Change	1615.07%	28.82%	-23.44%
Net Earnings / Revenue		-74040.0%	-39601.33%
Basic Earnings Per Share	-$3.59	-$0.67
Diluted Earnings Per Share	-$4.10	-$0.67	-$5.574M
COMMON SHARES
Basic Shares Outstanding	8.832M	2.774M	9.428M
Diluted Shares Outstanding	8.984M	2.774M

Balance Sheet

Concept	2021 Q2	2020 Q2	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$12.65M	$15.83M	$10.03M
YoY Change	-20.07%	594.3%	150.12%
Cash & Equivalents	$12.65M	$1.519M	$10.03M
Short-Term Investments
Other Short-Term Assets	$2.013M	$390.0K	$410.0K
YoY Change	416.15%	50.0%	36.67%
Inventory
Prepaid Expenses		$390.6K	$414.7K
Receivables	$59.00K	$16.94K	$19.01K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$14.73M	$16.24M	$10.46M
YoY Change	-9.34%	499.77%	130.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.000K	$21.70K	$31.13K
YoY Change	-86.17%	-65.8%	-58.86%
Goodwill
YoY Change
Intangibles		$630.6K	$649.7K
YoY Change		-11.6%	-12.01%
Long-Term Investments
YoY Change
Other Assets	$26.00K	$20.00K	$30.00K
YoY Change	30.0%	-45.8%	-43.77%
Total Long-Term Assets	$224.0K	$859.2K	$896.8K
YoY Change	-73.93%	5.61%	3.39%
TOTAL ASSETS
Total Short-Term Assets	$14.73M	$16.24M	$10.46M
Total Long-Term Assets	$224.0K	$859.2K	$896.8K
Total Assets	$14.95M	$17.10M	$11.36M
YoY Change	-12.59%	385.61%	110.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.406M	$540.0K	$960.0K
YoY Change	160.37%	-48.57%	-11.11%
Accrued Expenses	$955.0K	$130.0K	$130.0K
YoY Change	634.62%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.141M
YoY Change
Total Short-Term Liabilities	$3.850M	$676.0K	$1.186M
YoY Change	469.55%	-36.9%	-1.97%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$20.54M	$190.0K	$200.0K
YoY Change	10712.11%	-61.22%	-78.26%
Total Long-Term Liabilities	$0.00	$190.0K	$200.0K
YoY Change	-100.0%	-61.22%	-78.26%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.850M	$676.0K	$1.186M
Total Long-Term Liabilities	$0.00	$190.0K	$200.0K
Total Liabilities	$24.39M	$867.4K	$1.383M
YoY Change	2712.3%	-44.37%	-35.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$103.8M	-$231.5M	-$229.6M
YoY Change	-55.16%	6.11%	5.91%
Common Stock	$114.0K	$173.0K	$94.28K
YoY Change	-34.09%	1626.46%	-48.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$9.444M	-$11.68M	-$10.23M
YoY Change
Total Liabilities & Shareholders Equity	$14.95M	$17.10M	$11.36M
YoY Change	-12.59%	385.61%	110.16%

Cashflow Statement

Concept	2021 Q2	2020 Q2	2020 Q1
OPERATING ACTIVITIES
Net Income	-$31.75M	-$1.851M	-$2.384M
YoY Change	1615.07%	28.82%	-23.44%
Depreciation, Depletion And Amortization	-$8.000K	$30.00K	$30.00K
YoY Change	-126.67%	-25.0%	-25.0%
Cash From Operating Activities	-$5.032M	-$2.070M	-$1.678M
YoY Change	143.09%	26.22%	0.7%
INVESTING ACTIVITIES
Capital Expenditures	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$294.0K	$0.00	$0.00
YoY Change
Cash From Investing Activities	$294.0K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	20.62M	7.880M	6.593M
YoY Change	161.65%	-9950.0%	-5734.49%
NET CHANGE
Cash From Operating Activities	-5.032M	-2.070M	-1.678M
Cash From Investing Activities	294.0K	0.000
Cash From Financing Activities	20.62M	7.880M	6.593M
Net Change In Cash	15.88M	5.810M	4.915M
YoY Change	173.32%	-437.79%	-375.68%
FREE CASH FLOW
Cash From Operating Activities	-$5.032M	-$2.070M	-$1.678M
Capital Expenditures	$0.00
Free Cash Flow	-$5.032M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Registrant Name EntityRegistrantName	PALISADE BIO, INC.
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11398698
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
	dei	Entity Central Index Key EntityCentralIndexKey	0001357459
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12653000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	94000	USD
CY2021Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	26000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	26000	USD
CY2021Q2	pali	Deferred Merger Transaction Costs DeferredMergerTransactionCosts	0	USD
CY2020Q4	pali	Deferred Merger Transaction Costs DeferredMergerTransactionCosts	1817000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	195000	USD
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	6797500
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11398698
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11398698
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2774502
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2774502
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	26000	USD
CY2020Q2	pali	Rent Deferral Agreement Related To The Covid19 Pandemic Proration Of Deferred Balance Period RentDeferralAgreementRelatedToTheCOVID19PandemicProrationOfDeferredBalancePeriod	P6M
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12653000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	713000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	59000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	59000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2013000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	124000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	14725000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	896000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	275000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5000	USD
CY2021Q2	us-gaap	Assets Assets	14949000	USD
CY2020Q4	us-gaap	Assets Assets	3019000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1406000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2537000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	955000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2740000	USD
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	164000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1590000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	184000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	168000	USD
CY2021Q2	pali	Long Term Debt Current Maturities Excluding Related Party Debt LongTermDebtCurrentMaturitiesExcludingRelatedPartyDebt	696000	USD
CY2020Q4	pali	Long Term Debt Current Maturities Excluding Related Party Debt LongTermDebtCurrentMaturitiesExcludingRelatedPartyDebt	578000	USD
CY2021Q2	pali	Long Term Debt Related Party Current Maturities LongTermDebtRelatedPartyCurrentMaturities	445000	USD
CY2020Q4	pali	Long Term Debt Related Party Current Maturities LongTermDebtRelatedPartyCurrentMaturities	469000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3850000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8082000	USD
CY2021Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	20526000	USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1830000	USD
CY2021Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	112000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	24393000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	10118000	USD
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	114000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	28000	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	94242000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	51396000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103802000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-68026000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-9444000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-16602000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14949000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3019000	USD
CY2021Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	314000	USD
CY2020Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	650000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1006000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1902000	USD
CY2021Q2	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	30117000	USD
CY2020Q2	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	30117000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2427000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1191000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3688000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2334000	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	32858000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	1841000	USD
	us-gaap	Operating Expenses OperatingExpenses	34811000	USD
	us-gaap	Operating Expenses OperatingExpenses	4236000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-32858000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1841000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-34811000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4236000	USD
CY2021Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	279000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021Q2	pali	Loss On Issuance Of Secured Debt LossOnIssuanceOfSecuredDebt	-0	USD
CY2020Q2	pali	Loss On Issuance Of Secured Debt LossOnIssuanceOfSecuredDebt	-0	USD
	pali	Loss On Issuance Of Secured Debt LossOnIssuanceOfSecuredDebt	686000	USD
	pali	Loss On Issuance Of Secured Debt LossOnIssuanceOfSecuredDebt	-0	USD
CY2021Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	5133000	USD
CY2020Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	5175000	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2021Q2	pali	Gain Loss From Change In Fair Value Of Share Liability GainLossFromChangeInFairValueOfShareLiability	73000	USD
CY2020Q2	pali	Gain Loss From Change In Fair Value Of Share Liability GainLossFromChangeInFairValueOfShareLiability	0	USD
	pali	Gain Loss From Change In Fair Value Of Share Liability GainLossFromChangeInFairValueOfShareLiability	73000	USD
	pali	Gain Loss From Change In Fair Value Of Share Liability GainLossFromChangeInFairValueOfShareLiability	0	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	655000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	11000	USD
	us-gaap	Interest Expense InterestExpense	2367000	USD
	us-gaap	Interest Expense InterestExpense	11000	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	16000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	16000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12000	USD
CY2021Q2	pali	Loss On Issuance Of Preferred Stock LossOnIssuanceOfPreferredStock	1881000	USD
CY2020Q2	pali	Loss On Issuance Of Preferred Stock LossOnIssuanceOfPreferredStock	-0	USD
	pali	Loss On Issuance Of Preferred Stock LossOnIssuanceOfPreferredStock	1881000	USD
	pali	Loss On Issuance Of Preferred Stock LossOnIssuanceOfPreferredStock	-0	USD
CY2021Q2	pali	Financing Cost Derivative Warrant Liabilities FinancingCostDerivativeWarrantLiabilities	1574000	USD
CY2020Q2	pali	Financing Cost Derivative Warrant Liabilities FinancingCostDerivativeWarrantLiabilities	-0	USD
	pali	Financing Cost Derivative Warrant Liabilities FinancingCostDerivativeWarrantLiabilities	1574000	USD
	pali	Financing Cost Derivative Warrant Liabilities FinancingCostDerivativeWarrantLiabilities	-0	USD
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1112000	USD
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-965000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-31746000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-1851000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-35776000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4235000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.59
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.53
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.10
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.96
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.53
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8831517
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2774296
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5803010
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2774237
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8984198
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2774296
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5879351
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2774237
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-31746000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-1851000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-35776000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4235000	USD
CY2021Q2	us-gaap	Dilutive Securities DilutiveSecurities	-5119000	USD
CY2020Q2	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
	us-gaap	Dilutive Securities DilutiveSecurities	-5119000	USD
	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-36865000	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1851000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-40895000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4235000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-16602000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	569000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4030000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-20063000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	495000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1184000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	16000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	28728000	USD
CY2021Q2	pali	Stock Acquired During Period Value StockAcquiredDuringPeriodValue	2000	USD
CY2021Q2	pali	Adjustments To Additional Paid In Capital Restricted Stock Units Vested Upon Merger AdjustmentsToAdditionalPaidInCapitalRestrictedStockUnitsVestedUponMerger	41000	USD
CY2021Q2	pali	Adjustments To Additional Paid In Capital Equity Warrant Put Rights Activated Upon Merger AdjustmentsToAdditionalPaidInCapitalEquityWarrantPutRightsActivatedUponMerger	51000	USD
CY2021Q2	pali	Adjustments To Additional Paid In Capital Expiration Of Put Rights On Equity Classified Warrants AdjustmentsToAdditionalPaidInCapitalExpirationOfPutRightsOnEquityClassifiedWarrants	26000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-31746000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-9444000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-8332000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	487000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-2384000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-10229000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	393000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	9000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-1851000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-11678000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-35776000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4235000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	30117000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
	pali	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities Noncash Transaction Costs Shared With Acquiree AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesNoncashTransactionCostsSharedWithAcquiree	-135000	USD
	pali	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities Noncash Transaction Costs Shared With Acquiree AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesNoncashTransactionCostsSharedWithAcquiree	0	USD
	pali	Noncash Lease Expense NoncashLeaseExpense	80000	USD
	pali	Noncash Lease Expense NoncashLeaseExpense	3000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	279000	USD
	pali	Vesting Expense Restricted Stock Units VestingExpenseRestrictedStockUnits	41000	USD
	pali	Vesting Expense Restricted Stock Units VestingExpenseRestrictedStockUnits	0	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-0	USD
	pali	Gain Loss From Change In Fair Value Of Share Liability GainLossFromChangeInFairValueOfShareLiability	73000	USD
	pali	Gain Loss From Change In Fair Value Of Share Liability GainLossFromChangeInFairValueOfShareLiability	-0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1064000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	880000	USD
	pali	Accounts Payable Written Off AccountsPayableWrittenOff	183000	USD
	pali	Accounts Payable Written Off AccountsPayableWrittenOff	0	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	19900000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	99000	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	-0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	148000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	-0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	20618000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	279000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	USD
	us-gaap	Accretion Expense AccretionExpense	2203000	USD
	us-gaap	Accretion Expense AccretionExpense	12000	USD
	pali	Loss On Issuance Of Preferred Stock LossOnIssuanceOfPreferredStock	1881000	USD
	pali	Loss On Issuance Of Preferred Stock LossOnIssuanceOfPreferredStock	0	USD
	pali	Loss On Issuance Of Secured Debt LossOnIssuanceOfSecuredDebt	686000	USD
	pali	Loss On Issuance Of Secured Debt LossOnIssuanceOfSecuredDebt	0	USD
	pali	Issuance Cost Allocated To Warrants IssuanceCostAllocatedToWarrants	1574000	USD
	pali	Issuance Cost Allocated To Warrants IssuanceCostAllocatedToWarrants	0	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	5175000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-25000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	53000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1294000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-43000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2499000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	998000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1518000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	0	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-79000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8972000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2351000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	3279000	USD
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	2985000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	-0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	294000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6000	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	285000	USD
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	-0	USD
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1250000	USD
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	279000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11940000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2078000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	739000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3623000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12679000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1545000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1519000	USD
CY2021Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	26000	USD
CY2020Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	26000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12679000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1545000	USD
	us-gaap	Interest Paid Net InterestPaidNet	50000	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	pali	Noncash Transaction Costs Shared With Acquiree NoncashTransactionCostsSharedWithAcquiree	135000	USD
	pali	Noncash Transaction Costs Shared With Acquiree NoncashTransactionCostsSharedWithAcquiree	0	USD
	pali	Acquisitionrelated Costs Included In Accounts Payable And Accrued Liabilities AcquisitionrelatedCostsIncludedInAccountsPayableAndAccruedLiabilities	367000	USD
	pali	Acquisitionrelated Costs Included In Accounts Payable And Accrued Liabilities AcquisitionrelatedCostsIncludedInAccountsPayableAndAccruedLiabilities	0	USD
	pali	Acquisition Costs Related To Stock Issuance AcquisitionCostsRelatedToStockIssuance	1184000	USD
	pali	Acquisition Costs Related To Stock Issuance AcquisitionCostsRelatedToStockIssuance	0	USD
	pali	Issuance Of Common Stock To Former Shareholders Of Acquiree IssuanceOfCommonStockToFormerShareholdersOfAcquiree	28728000	USD
	pali	Issuance Of Common Stock To Former Shareholders Of Acquiree IssuanceOfCommonStockToFormerShareholdersOfAcquiree	0	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	9503000	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
	pali	Assets Assumed1 AssetsAssumed1	2000	USD
	pali	Assets Assumed1 AssetsAssumed1	0	USD
	pali	Acquisition Related Vesting Of Rsus Assumed In Merger AcquisitionRelatedVestingOfRsusAssumedInMerger	41000	USD
	pali	Acquisition Related Vesting Of Rsus Assumed In Merger AcquisitionRelatedVestingOfRsusAssumedInMerger	0	USD
	pali	Acquisition Related Fair Value Change In Warrant Liability Assumed In Merger AcquisitionRelatedFairValueChangeInWarrantLiabilityAssumedInMerger	51000	USD
	pali	Acquisition Related Fair Value Change In Warrant Liability Assumed In Merger AcquisitionRelatedFairValueChangeInWarrantLiabilityAssumedInMerger	0	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103800000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12700000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b><i>Use of Estimates </i></b></p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s financial statements and notes. The most significant estimates in the Company’s financial statements relate to clinical trial accruals and valuation of derivative liabilities and stock-based compensation. Although these estimates are based on the Company’s knowledge of current events and actions it <em style="font: inherit;"> may </em>undertake in the future, actual results <em style="font: inherit;"> may </em>materially differ from these estimates and assumptions.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"> </p>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2021Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	26000	USD
CY2021Q2	pali	Deferred Merger Transaction Costs DeferredMergerTransactionCosts	0	USD
CY2020Q4	pali	Deferred Merger Transaction Costs DeferredMergerTransactionCosts	1800000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Concentration of Credit Risk</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions and in money market accounts, and at times balances <em style="font: inherit;"> may </em>exceed federally insured limits. Management believes that the Company is <em style="font: inherit;">not</em> exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held nor has the Company experienced any losses in these accounts.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8831517
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2774296
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5803010
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2774237
CY2021Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	152681
CY2020Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	76341
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8984198
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2774296
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5879351
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2774237
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1668919
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1213142
CY2021Q2	pali	Number Of Directors NumberOfDirectors	8	pure
CY2021Q2	pali	Accrued Accounts Payable AccruedAccountsPayable	201000	USD
CY2020Q4	pali	Accrued Accounts Payable AccruedAccountsPayable	1018000	USD
CY2021Q2	pali	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	589000	USD
CY2020Q4	pali	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	875000	USD
CY2021Q2	pali	Accrued Director Stipends AccruedDirectorStipends	85000	USD
CY2020Q4	pali	Accrued Director Stipends AccruedDirectorStipends	759000	USD
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	80000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	88000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	955000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2740000	USD
CY2021Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1155000	USD
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2719000	USD
CY2021Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	14000	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1578000	USD
CY2021Q2	us-gaap	Long Term Debt LongTermDebt	1141000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	1141000	USD
CY2021Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	1141000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1047000	USD
CY2021Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	94000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	553000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	602000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	USD
CY2021Q2	pali	Longterm Debt Maturity Year Three And Thereafter LongtermDebtMaturityYearThreeAndThereafter	0	USD
CY2021Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1155000	USD
CY2021Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	14000	USD
CY2021Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	-0	USD
CY2021Q2	us-gaap	Long Term Debt LongTermDebt	1141000	USD
CY2021Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	1141000	USD
CY2021Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q2	pali	Number Of Votes Per Share Of Common Stock NumberOfVotesPerShareOfCommonStock	1	pure
CY2021Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	7013629	USD
CY2020Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	195712	USD
CY2020Q4	pali	Class Of Warrant Or Right Number Outstanding ClassOfWarrantOrRightNumberOutstanding	195712
CY2020	pali	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	21.20
CY2020	pali	Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife	P6Y7M6D
CY2021Q1	pali	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	94096
CY2021Q1	pali	Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice	17.72
CY2021Q1	pali	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	-0
CY2021Q1	pali	Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod	-0
CY2021Q1	pali	Class Of Warrant Or Right Number Outstanding ClassOfWarrantOrRightNumberOutstanding	289808
CY2021Q1	pali	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	10.81
CY2021Q1	pali	Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife	P6Y10D
CY2021Q2	pali	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	6000621
CY2021Q2	pali	Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice	3.93
CY2021Q2	pali	Class Of Warrant Or Right Assumed During Period ClassOfWarrantOrRightAssumedDuringPeriod	749792
CY2021Q2	pali	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	-0
CY2021Q2	pali	Class Of Warrant Or Right Settled During Period ClassOfWarrantOrRightSettledDuringPeriod	20313
CY2021Q2	pali	Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod	6279
CY2021Q2	pali	Class Of Warrant Or Right Number Outstanding ClassOfWarrantOrRightNumberOutstanding	7013629
CY2021Q2	pali	Class Of Warrant Or Right Outstanding Weighted Average Exercise Price ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice	6.07
CY2021Q2	pali	Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife	P4Y11M12D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	826769
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.72
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y5M26D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1541000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	59818
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	17.72
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	84132
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	802455
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	33.11
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	802455
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	33.11
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y9M
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	759743
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	33.19
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y7M28D
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.15
CY2021Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	600000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M6D
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	495000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	393000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1064000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	880000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y11M23D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7605	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.800	pure
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	195000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	275000	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	201000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	280000	USD
CY2021Q2	pali	Rent Deferral Agreement Related To The Covid19 Pandemic Deferred Balance RentDeferralAgreementRelatedToTheCovid19PandemicDeferredBalance	0	USD
CY2020Q4	pali	Rent Deferral Agreement Related To The Covid19 Pandemic Deferred Balance RentDeferralAgreementRelatedToTheCovid19PandemicDeferredBalance	87000	USD
CY2020Q4	pali	Accrual For Suspended Salary Benefits And Bonuses To Be Paid Upon Closing Of Merger AccrualForSuspendedSalaryBenefitsAndBonusesToBePaidUponClosingOfMerger	1100000	USD
CY2021Q2	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	85000	USD
CY2020Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	759000	USD

Files In Submission

Name	View Source	Status
0001171843-21-006102-index-headers.html	Edgar Link	pending
0001171843-21-006102-index.html	Edgar Link	pending
0001171843-21-006102.txt	Edgar Link	pending
0001171843-21-006102-xbrl.zip	Edgar Link	pending
ex_276872.htm	Edgar Link	pending
ex_276873.htm	Edgar Link	pending
ex_276874.htm	Edgar Link	pending
ex_276875.htm	Edgar Link	pending
ex_276876.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
intestine.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pali-20210630.xsd	Edgar Link	pending
pali-20210630_cal.xml	Edgar Link	unprocessable
pali-20210630_def.xml	Edgar Link	unprocessable
pali-20210630_lab.xml	Edgar Link	unprocessable
pali-20210630_pre.xml	Edgar Link	unprocessable
pali20210630_10q.htm	Edgar Link	pending
pali20210630_10q_htm.xml	Edgar Link	completed
pipeline.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PALI
PALISADE BIO, INC. Stock $pali

2021 Q2 Form 10-Q Financial Statement

#000117184321006102 Filed on August 23, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PALI PALISADE BIO, INC. Stock $pali

2021 Q2 Form 10-Q Financial Statement

#000117184321006102 Filed on August 23, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PALI
PALISADE BIO, INC. Stock $pali